This article is more than 5 years old. Information may no longer be current.

InnoCore, Allergan sign license, collaboration agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan, according to a news release.

Under the agreement, the companies will expand their existing collaboration and continue to develop long-acting ocular drug delivery products to treat ophthalmic diseases, the release said.

InnoCore will use its SynBiosys polymeric drug delivery platform to formulate Allergan’s proprietary drugs into pharmaceutical products that can provide sustained release for several months after a single ocular injection, according to the release.